Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Faculty of Medicine, Menoufia University, Menoufia, Egypt.
BMC Endocr Disord. 2022 Apr 29;22(1):113. doi: 10.1186/s12902-022-01031-5.
The food and drug administration approved many drugs to treat diabetes mellitus, but those drugs do not have a noticeable effect on weight management. Recently, glucagon-like peptide 1 agonist known as Cotadutide serve as a potent drug in treating type 2 diabetes by reducing blood glucose levels and body weight indices. This study aimed to explore the safety and efficacy of Cotadutide as a treatment for type 2 diabetes individuals.
A comprehensive literature search was done on different databases, including PubMed, Scopus, Web of Science, and Cochrane Library to capture all relevant articles using an established search strategy. The inclusion criteria were randomized controlled trials that assessed the safety and efficacy of Cotadutide versus placebo or any anti-diabetes drugs in patients with type 2 diabetes mellitus and a BMI between 22 kg/m and 40 kg/m. We conducted the analysis using Revman software version 5.4.
We found 663 relevant articles. From which nine studies were included and subjected to qualitative analysis and eight for quantitative analysis. The pooled effect showed that Cotadutide was better than placebo in reducing body weight (kg) (Mean difference (MD) = 3.31, p < 0.00001), glycated hemoglobin (HbA) (MD = 0.68, p > 0.00001), glucose area under the plasma concentration curve (AUC [0-4 h]) (MD = 30.15, p < 0.00001), and fasting plasma glucose over time (mg/dl) (MD = 31.31, p < 0.00001).
Cotadutide is safe and effective in reducing plasma glucose levels, HbA and body weight in individuals with type 2 diabetes.
The study protocol was registered on PROSPERO (CRD: CRD42021257670 ).
食品和药物管理局批准了许多治疗糖尿病的药物，但这些药物在体重管理方面没有明显效果。最近，胰高血糖素样肽 1 激动剂 Cotadutide 作为一种治疗 2 型糖尿病的有效药物，通过降低血糖水平和体重指数发挥作用。本研究旨在探讨 Cotadutide 作为 2 型糖尿病患者治疗药物的安全性和有效性。
我们在不同的数据库（包括 PubMed、Scopus、Web of Science 和 Cochrane Library）上进行了全面的文献检索，使用既定的搜索策略捕获所有相关文章。纳入标准为评估 Cotadutide 与安慰剂或任何抗糖尿病药物在 BMI 为 22kg/m² 至 40kg/m²的 2 型糖尿病患者中的安全性和疗效的随机对照试验。我们使用 Revman 软件版本 5.4 进行分析。
我们发现了 663 篇相关文章。其中 9 项研究被纳入并进行了定性分析，8 项进行了定量分析。汇总结果显示，Cotadutide 在降低体重（kg）（MD=3.31，p<0.00001）、糖化血红蛋白（HbA）（MD=0.68，p>0.00001）、血浆浓度曲线下面积（AUC [0-4h]）（MD=30.15，p<0.00001）和空腹血糖随时间的变化（mg/dl）（MD=31.31，p<0.00001）方面优于安慰剂。
Cotadutide 安全有效，可降低 2 型糖尿病患者的血糖水平、HbA 和体重。
本研究方案已在 PROSPERO（CRD: CRD42021257670）上注册。
